Literature DB >> 11864079

Comparative in vitro pharmacodynamics of BO-2727, meropenem and imipenem against Gram-positive and Gram-negative bacteria.

Inga Odenholt1, Elisabeth Löwdin, Otto Cars.   

Abstract

OBJECTIVE: To investigate and compare the in vitro pharmacodynamics of three carbapenems: imipenem, meropenem and BO-2727.
METHODS: The following studies were performed: (1) comparative studies of the rate of killing of the three carbapenems of reference strains of Gram-positive and Gram-negative bacteria at a concentration corresponding to the 1-h serum level following 500 mg intravenously in humans; (2) comparative studies of the rate of killing of BO-2727, meropenem and imipenem at different antibiotic concentrations of reference strains of Gram-positive and Gram-negative bacteria; (3) comparative studies of the rate of killing of BO-2727, meropenem and imipenem of bacteria which are phenotypically tolerant; (4) studies of the postantibiotic effect of BO-2727 using viable counts and optical density; (5) studies of the postantibiotic sub-MIC effect (PA SME) of BO-2727 using optical density.
RESULTS: No difference in killing rate was noted between the three carbapenems, and there was no concentration-dependent killing of the Gram-negative strains after 6 h. A pronounced paradoxical effect was seen against Staphylococcus aureus. All three antibiotics were able to kill phenotypically tolerant bacteria. Only very short or no postantibiotic effect of BO-2727 was found against the investigated strains. Very long PA SMEs were noted for the Gram-negative strains, although there was a pronounced variation for the different strains of Pseudomonas aeruginosa.
CONCLUSION: There was no significant difference between the studied carbapenems in their pharmacodynamic properties. All three antibiotics acted similarly to other beta-lactam antibiotics.

Entities:  

Year:  1997        PMID: 11864079     DOI: 10.1111/j.1469-0691.1997.tb00254.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  7 in total

1.  In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.

Authors:  Cédric Jacqueline; Dominique Navas; Eric Batard; Anne-Françoise Miegeville; Virginie Le Mabecque; Marie-France Kergueris; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.

Authors:  Inga Odenholt; Elisabeth Löwdin; Otto Cars
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

3.  In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria.

Authors:  I Odenholt; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

4.  Influence on Enterobacter cloacae metabolism, cell-surface hydrophobicity and motility of suprainhibitory concentrations of carbapenems.

Authors:  V Majtán; L Majtánová
Journal:  Folia Microbiol (Praha)       Date:  2001       Impact factor: 2.099

5.  Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin.

Authors:  Inga Odenholt; Elisabeth Löwdin; Otto Cars
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 6.  Ertapenem: a review of its use in the management of bacterial infections.

Authors:  Monique Curran; Dene Simpson; Caroline Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin

Authors:  Arpasiri Srisrattakarn; Chonthicha Chaiyapoke; Sirikarn Booncharoen; Sujintana Wongthong; Aroonwadee Chanawong; Patcharaporn Tippayawat; Ratree Tavichakorntrakool; Aroonlug Lulitanond
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.